Your browser doesn't support javascript.
loading
Related quality of life questionnaire specific to dysthyroid ophthalmopathy evaluated in a population of patients with Graves' disease.
Delfino, Laura Carolina; Zunino, Anabela; Sapia, Verónica; Croome, María Del Carmen Silva; Ilera, Verónica; Gauna, Alicia Teresa.
Afiliação
  • Delfino LC; División Endocrinología, Hospital de Agudos J. M. Ramos Mejía, Ciudad Autónoma de Buenos Aires, Argentina.
  • Zunino A; División Endocrinología, Hospital de Agudos J. M. Ramos Mejía, Ciudad Autónoma de Buenos Aires, Argentina.
  • Sapia V; Servicio de Oftalmología, Hospital de Agudos J. M. Ramos Mejía, Ciudad Autónoma de Buenos Aires, Argentina.
  • Croome MDCS; División Endocrinología, Hospital de Agudos J. M. Ramos Mejía, Ciudad Autónoma de Buenos Aires, Argentina.
  • Ilera V; División Endocrinología, Hospital de Agudos J. M. Ramos Mejía, Ciudad Autónoma de Buenos Aires, Argentina.
  • Gauna AT; División Endocrinología, Hospital de Agudos J. M. Ramos Mejía, Ciudad Autónoma de Buenos Aires, Argentina.
Arch Endocrinol Metab ; 61(4): 374-381, 2017.
Article em En | MEDLINE | ID: mdl-28225858
ABSTRACT

OBJECTIVE:

The aim of this study was to measure quality of life (QOL) impairment in individuals currently suffering from Graves' ophthalmopathy (GO) and to determine the correlation of GO-specific QOL scores with disease severity and activity. SUBJECTS AND

METHODS:

Seventy three GO-specific QOL surveys were prospectively analysed and compared with GO status. The GO-specific QOL survey was translated into Spanish and applied to Argentine patients with Graves' disease (GD). Results were compared with presence or absence of GO, Clinical Activity Score (CAS), severity score, age, gender and thyroid function.

RESULTS:

Fifty-six patients answered the survey and underwent complete ophthalmic evaluation, 15 did not have GO and were considered to be a control group. Appearance QOL score for patients with GO (53 ± 31.4) was lower than the control group (88.3 ± 17) (p < 0,000), no difference was observed in functional QOL score. There was a negative correlation between GO severity and both functional (r = -0.575; p < 0.000) and appearance QOL (r = -0.577; p < 0.000). Functional QOL differed between patients with active GO vs control group (p = 0.043). Patients with active and inactive GO had lower appearance QOL scores than control group (p < 0.000, p < 0.001 respectively).

CONCLUSIONS:

GO has significant impact on the life of these Argentine patients. QOL was worse in GO patients than in control group, functional QOL was mostly affected by the activity and appearance QOL was mainly altered by the effects of the disease. Patients with more severe GO had lower scores on both QOL scales.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Qualidade de Vida / Inquéritos e Questionários / Oftalmopatia de Graves Tipo de estudo: Observational_studies / Prevalence_studies / Qualitative_research / Risk_factors_studies Limite: Adult / Female / Humans / Male / Middle aged País/Região como assunto: America do sul / Argentina Idioma: En Revista: Arch Endocrinol Metab Ano de publicação: 2017 Tipo de documento: Article País de afiliação: Argentina

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Qualidade de Vida / Inquéritos e Questionários / Oftalmopatia de Graves Tipo de estudo: Observational_studies / Prevalence_studies / Qualitative_research / Risk_factors_studies Limite: Adult / Female / Humans / Male / Middle aged País/Região como assunto: America do sul / Argentina Idioma: En Revista: Arch Endocrinol Metab Ano de publicação: 2017 Tipo de documento: Article País de afiliação: Argentina